Idexx LaboratoriesIDXX
IDXX
About: Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Employees: 11,000
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 12 [Q4 2024] → 18 (+6) [Q1 2025]
33% more first-time investments, than exits
New positions opened: 120 | Existing positions closed: 90
31% more repeat investments, than reductions
Existing positions increased: 456 | Existing positions reduced: 349
3.13% more ownership
Funds ownership: 87.57% [Q4 2024] → 90.69% (+3.13%) [Q1 2025]
4% more capital invested
Capital invested by funds: $29.7B [Q4 2024] → $30.8B (+$1.18B) [Q1 2025]
1% more funds holding
Funds holding: 1,104 [Q4 2024] → 1,115 (+11) [Q1 2025]
34% less call options, than puts
Call options by funds: $68.7M | Put options by funds: $105M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$475
11%
downside
Avg. target
$538
1%
upside
High target
$580
9%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
Stifel Jonathan Block | 1%upside $540 | Hold Maintained | 2 Jul 2025 |
Leerink Partners Daniel Clark | 9%upside $580 | Outperform Maintained | 11 Jun 2025 |
Morgan Stanley Erin Wright | 5%upside $558 | Overweight Maintained | 5 May 2025 |
B of A Securities Michael Ryskin | 11%downside $475 | Neutral Maintained | 21 Apr 2025 |
Financial journalist opinion
Based on 4 articles about IDXX published over the past 30 days
Positive
Zacks Investment Research
1 day ago
Idexx (IDXX) is an Incredible Growth Stock: 3 Reasons Why
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
Neutral
Business Wire
1 day ago
IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. “Jay is an accomplished executive who brings extensive strategic thinking and financial leadership experience, alon.
Positive
Zacks Investment Research
4 days ago
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Neutral
Business Wire
2 weeks ago
IDEXX Laboratories to Release 2025 Second Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2025 Earnings Snapshot through a link on the IDEXX websi.
Neutral
PRNewsWire
1 month ago
Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders
The Catalyst ® Cortisol Test provides veterinarians with real-time critical insights when evaluating dogs for Addison's disease and Cushing's syndrome WESTBROOK, Maine , June 5, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst® Cortisol Test, which measures real-time quantitative cortisol concentrations to support the diagnosis of Addison's disease and diagnosis and management of Cushing's syndrome in dogs. IDEXX's Catalyst Cortisol Test is the third menu expansion in under a year for the Catalyst platform, further advancing the diagnostic capabilities available to veterinary practices at the point-of-care.
Positive
Zacks Investment Research
1 month ago
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
Neutral
Seeking Alpha
1 month ago
IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits
IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normalization of consumer spending, and robust pricing power supporting profit growth. Management guides for 6%-9% organic revenue and 8%-12% adjusted EPS growth in FY25; I model 8.2% revenue growth and margin expansion.
Positive
Zacks Investment Research
1 month ago
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
Neutral
Business Wire
1 month ago
IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation will be available through a link on.
Positive
Zacks Investment Research
2 months ago
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Charts implemented using Lightweight Charts™